Lohmann's medical sales down again in 1994
This article was originally published in Clinica
Executive Summary
German woundcare manufacturer Lohmann has suffered a second year of declining sales in its medical division in 1994. Total revenues, on the other hand, stabilised after a 5% fall in 1993. Lohmann's medical division contributed 53% or DM 200 million ($134 million) to total sales, down 3.8% with declines seen both in Germany and abroad. Lohmann blames price cuts averaging 5.5% which were only partly offset by a 1.7% increase in volume.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.